On August 18, 2021, Harrow Health Inc. entered into a License Agreement and a Basic Sale and Purchase Agreement with Wakamoto Pharmaceutical Co. Ltd., pursuant to which Wakamoto granted the Company the exclusive license and marketing rights to its ophthalmic drug candidate (MAQ-100) in the United States of America (U.S.) and Canada. Pursuant to the Agreements, Wakamoto will supply MAQ-100 to the Company, and the Company will pay Wakamoto a per unit transfer price to supply MAQ-100. In addition, the Company is required to pay Wakamoto various one-time milestone payments totaling up to $2,000,000 upon the achievement of certain regulatory milestones and up to $6,200,000 upon the achievement of certain commercial milestones. Under the terms of the Agreements, the Company will be responsible for regulatory filings and fees for MAQ-100 in the U.S. and Canada. Subject to certain limitations, the term of the Agreements is for five years from the date of the U.S. Food and Drug Administration's (or FDA's) market approval of MAQ-100 and allows for a five-year extension if certain unit sales thresholds are met.